Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

[News]

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has revealed new results from a global survey demonstrating that 66% of patients with metastatic colorectal cancer (mCRC) are now tested for KRAS to determine if they could benefit from a personalized therapy, such as Erbitux® (cetuximab). This represents a 50% increase in levels of KRAS testing in just one year.

More... (http://www.news-medical.net/news/20100701/Survey-6625-of-patients-with-metastatic-colorectal-cancer-are-now-tested-for-KRAS.aspx)